As the Asian markets navigate a landscape marked by geopolitical uncertainties and fluctuating economic indicators, investors are increasingly focused on identifying growth opportunities. In this context, companies with strong insider ownership can offer a unique appeal, as they often signal confidence in the company's potential and alignment of interests between management and shareholders.
| Name | Insider Ownership | Earnings Growth |
| Suzhou Dongshan Precision Manufacturing (SZSE:002384) | 33.5% | 73.1% |
| Ningbo Sanxing Medical ElectricLtd (SHSE:601567) | 24.9% | 45.6% |
| Meiko Electronics (TSE:6787) | 19.2% | 30.1% |
| Jiangxi Fushine Pharmaceutical (SZSE:300497) | 21.1% | 50.8% |
| HUMAN MADE (TSE:456A) | 23.9% | 23.4% |
| Guangzhou Tinci Materials Technology (SZSE:002709) | 38.4% | 28.3% |
| Great Microwave Technology (SHSE:688270) | 29.5% | 85.5% |
| Gpixel Changchun Microelectronics (SEHK:3277) | 18.2% | 34.2% |
| Fulin Precision (SZSE:300432) | 11.2% | 60.7% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 14.1% | 41% |
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: UMS Integration Limited is an investment holding company that offers equipment manufacturing and engineering services to semiconductor original equipment manufacturers across multiple countries, with a market cap of SGD2.42 billion.
Operations: UMS Integration Limited's revenue is primarily derived from providing manufacturing and engineering services to semiconductor OEMs across various international markets.
Insider Ownership: 14.2%
UMS Integration shows promising growth, with earnings increasing by 32.1% over the past year and a forecasted annual profit growth of 23.1%, outpacing the SG market. Despite its volatile share price, it trades at a favorable P/E ratio of 44x compared to the industry average. Recent earnings announcements highlight strong performance, with significant increases in sales and net income for Q2 and H1 2026, reinforcing its growth trajectory amidst high insider ownership stability.
Simply Wall St Growth Rating: ★★★★★☆
Overview: APT Medical Inc. is involved in the research, development, production, and sale of cardiovascular interventional medical devices in China with a market cap of CN¥30.74 billion.
Operations: The company generates revenue of CN¥2.72 billion from its cardiovascular interventional medical devices segment in China.
Insider Ownership: 20.1%
APT Medical demonstrates strong growth potential, with earnings forecasted to grow significantly at 22.22% annually and revenue expected to outpace the Chinese market at 21.8% per year. The stock is trading 46.1% below its estimated fair value, suggesting room for price appreciation as analysts anticipate a rise of 47.4%. Recent share buybacks totaling CNY 99.98 million reflect management's confidence despite an unstable dividend track record, contributing to its high insider ownership appeal in Asia.
Simply Wall St Growth Rating: ★★★★★☆
Overview: freee K.K. provides cloud-based accounting and HR software solutions in Japan, with a market cap of ¥198.63 billion.
Operations: The company generates revenue from its Platform Business segment, which amounted to ¥42.44 billion.
Insider Ownership: 25.4%
freee K.K. shows potential for growth with its revenue forecasted to grow at 16.1% annually, outpacing the Japanese market average of 6.1%. Earnings are expected to rise significantly by 43.9% per year, though recent earnings results indicate a decline in net income and profit margins compared to last year. The stock trades at a significant discount of 53.3% below its estimated fair value, while high insider ownership remains attractive despite recent index exclusion and share price volatility.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com